Germany's Multiple Myeloma Therapeutics Market was valued at $305 Mn in 2022 and is estimated to expand at a CAGR of 2.7% from 2022-30 and will reach $378 Mn in 2030. One of the main reasons propelling the growth of this Market is an increase in chronic disease, Increasing adoption of combination therapies. The Market is segmented by type, drug and distribution channel. Some key players in this Market are Abbott, MorphoSys, Merck, Medigene, Affimed, Helios Hospital, Vivantes Hospital Group and others.
Germany's Multiple Myeloma Therapeutics Market was valued at $305 Mn in 2022 and is estimated to expand at a CAGR of 2.7% from 2022-30 and will reach $378 Mn in 2030. Multiple myeloma and plasma cell neoplasms are malignant growths of plasma cells that produce antibodies. This type of cancer typically begins in the bone marrow, where it frequently forms several disease foci (multiple myeloma) with consequences such as bone fractures, discomfort, and blood count aMnormalities. Around 1% of cases are identified in organs other than bone marrow (extramedullary plasmacytoma). In Germany, multiple myeloma was diagnosed in approximately 2,949 women and 3,741 men in 2019. It is highly uncommon for a disease to be diagnosed before the age of 45, as the risk rises dramatically with age (about 1.5 percent of all cases). Current incidence and mortality rates among women and men have remained relatively stable when adjusted for age.
Market Growth Drivers
The incidence of multiple myeloma in Germany has been steadily increasing in recent years, which is driving demand for new and innovative therapeutics. Multiple myeloma is more prevalent in older adults, and as the population in Germany continues to age, the demand for multiple myeloma therapeutics is expected to increase. There have been significant advancements in the development of new drugs for multiple myeloma in recent years, including immunomodulatory drugs and monoclonal antibodies, which are driving growth in the market. Combination therapies, which involve the use of multiple drugs to treat multiple myeloma, have become increasingly common in Germany, as they have been shown to be more effective than single-agent therapies. The German healthcare system provides favorable reimbursement policies for cancer treatments, including multiple myeloma therapeutics, which is helping to drive growth in the market. There are several promising drugs in the pipeline for the treatment of multiple myeloma, which are expected to drive growth in the market in the coming years.
The German government and health insurers are placing increasing pressure on drug manufacturers to reduce prices, which is limiting the profitability of the market. There are several established and new players in the multiple myeloma therapeutics market, which is increasing competition and limiting pricing power. The regulatory approval process for new drugs in Germany can be time-consuming and expensive, which is limiting the availability of new and innovative treatments. Several key drugs used in the treatment of multiple myeloma are set to lose patent protection in the coming years, which is expected to increase competition from generic drugs and reduce revenues for branded drugs. While the German healthcare system provides universal coverage, access to specialized cancer centers and treatments may be limited in some areas, particularly in rural regions. Some multiple myeloma therapeutics are associated with adverse events and side effects, which can limit patient compliance and reduce demand for the drugs.
The German healthcare system is based on statutory health insurance, which covers the vast majority of the population. This means that the cost of multiple myeloma therapeutics is largely borne by health insurers. Drug prices are negotiated between pharmaceutical companies and the National Association of Statutory Health Insurance Funds (GKV-SV). These negotiations can be lengthy and are aimed at ensuring that prices are appropriate based on the clinical benefits of the drug. There are a number of cost containment measures in place in Germany, including reference pricing, which sets a maximum reimbursement price for drugs in a particular class, and rebates, which require drug manufacturers to pay a portion of their revenues back to health insurers.
New treatments for multiple myeloma are subject to benefit assessments by the Federal Joint Committee (G-BA), which evaluates the additional benefit of new treatments compared to existing therapies. Based on this assessment, a drug may be classified as having an "added benefit", "no added benefit", or "less benefit" compared to existing treatments. This classification can impact the level of reimbursement for the drug. Once a drug has been approved and classified by the G-BA, the price of the drug is negotiated between the pharmaceutical company and the National Association of Statutory Health Insurance Funds (GKV-SV). The goal of these negotiations is to set a fair and reasonable price for the drug based on the clinical benefits it provides. The reimbursement rates for multiple myeloma treatments are based on the diagnosis-related group (DRG) system, which assigns a fixed reimbursement amount for each patient based on their diagnosis. The reimbursement rates for multiple myeloma treatments are typically higher than for other conditions due to the complexity and cost of treating this disease.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
22.214.171.124 Product Applications and Services
126.96.36.199 Recent Developments
188.8.131.52 Partnerships Ecosystem
184.108.40.206 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Distribution Channel
By End User (Revenue, USD Bn):
By Drug Class
Immunomodulatory drugs (IMiDs)
One of the most common therapies used to treat myeloma are immunomodulatory drugs, or IMiDs. These drugs work by modifying the immune system to attack myeloma cells and have been a significant advance in the treatment of multiple myeloma. Some of the commonly used IMiDs in multiple myeloma include:
Proteasome inhibitors are a class of drugs that are commonly used in the treatment of multiple myeloma. They work by blocking the activity of proteasomes, which are cellular structures that break down proteins. This leads to the accumulation of proteins within the myeloma cells, ultimately causing their death. Some proteasome inhibitors used in multiple myeloma include:
Monoclonal antibodies, target specific proteins on the surface of myeloma cells, causing them to be destroyed by the immune system. Some of the commonly used monoclonal antibodies in multiple myeloma include:
Chemotherapy drugs work by killing rapidly dividing cells, including cancer cells. Chemotherapy is often used in combination with other drugs, such as steroids, immunomodulatory drugs, or proteasome inhibitors, to improve their effectiveness. Here are some chemotherapy drugs used in multiple myeloma:
Steroids such as dexamethasone and prednisone are often used in combination with other drugs to treat multiple myeloma. They can reduce inflammation, suppress the immune system, and promote the death of myeloma cells.
Steroids are effective in reducing inflammation and suppressing the immune system, which can help to control the growth of myeloma cells. However, they can have side effects, such as weight gain, mood changes, and increased risk of infection, so their use needs to be carefully monitored.
Other drug classes used to treat multiple myeloma include:
Insights10 will provide you with the reports within 10 key parameters which are:
Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.
Stage I: Market Data Collection
Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.
Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.
Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:
Stage II: Market Data Analysis and Statistical Model
Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.
Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.
The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.
The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.
Data Triangulation & Validation:
Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.
We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.
Stage III: Interpretation and Presentation
Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)
Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to oﬀer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.
Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.
Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.
The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
This report addresses